Sebi Confirms Restrictions on Par Drugs’ Proposed Slump Sale
Regulatory Action Pending Investigation
New Delhi, March 26 – The Securities and Exchange Board of India (Sebi) has confirmed its previous directions against Par Drugs and Chemicals Ltd (PDCL) regarding a proposed slump sale of its...
businesstransfer
financial transactions
india
investigation
par drugs and chemicals ltd
pdcl
phal-jig fine chemicals pvt ltd
pjfcpl
regulatory compliance
sebi
securities and exchange board of india
shareholder communication
slump sale
vadodara
valuation